Find out more

Find out more about the work of our committee sub-groups and forums by clicking the logos below. These include The British Viral Hepatitis Group, British Association for the Study of the Liver Nurse Forum and the British Liver Transplant Group.

The British Viral Hepatitis aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.

British Association for the Study of the Liver Nurse Forum is a professional nursing organisation aiming to develop knowledge and understanding of liver disease, in order to improve the quality of patient care.

The BLTG (British Liver Transplant Group) was launched in 2014 to represent the professional interests of liver transplantation in the UK and promote strategic and academic development.

Tweets

Join BASL

BASL is a multi-disciplinary society with around 850 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions. Your Annual subscription is used to organise the Annual Meeting held each September.

Members of BASL receive the following benefits:

  • discounted registration rates for the annual meeting and other relevant meetings
  • eligibility for the BASL Travel Awards (for members below status of Senior Lecturer or Consultant to allow presentation of high-quality UK liver research at International meetings, including the American Association for the Study of Liver Disease)
  • eligibility for the prestigious Dame Sheila Sherlock Award (to an emerging researcher in the field of liver disease, for members below status of Senior Lecturer or consultant). Applications are usually submitted to the BASL Committee three months prior to the annual meeting - details are announced.

Click here to find out more about joining us.

News

08/02/16 Short-term entecavir safe and effective in paediatric HBV
News Type: Clinical News

Entecavir in children and adolescents with chronic HBV is safe and shows clinical benefits in short-term biochemical and virologic responses, a new study concluded.

In the study, at the National Taiwan University Hospital, group one comprised nine treatment-naïve patients (median aged 12.2 years) who had been HBeAg seropositive for more than six months, and had alanine aminotransferase (ALT) of more than two times the upper limit of normal value (30 IU/L). They received entecavir at a dose of 0.015 mg/kg/d, with a maximal dose of 0.5 mg daily, for at least 52 weeks. Another 27 untreated chronic HBV patients matched for age, sex, ALT levels, and HBeAg status were recruited as the control group.

The entecavir-treated patients achieved rapid ALT normalisation (all before eight months of treatment) compared with the control group and had a greater chance of achieving undetectable HBV DNA levels at Week 52 after treatment (55.6% versus 11.1%).

The cumulative incidence rates of HBeAg seroconversion were similarly high in both groups (entecavir group 44% at one year and 78% at two years; control group 37% and 63%, respectively). The entecavir group also had a trend of better complete response than the control group (22.2% versus 0%). None of the entecavir-treated patients reported significant adverse effects.

Reference

Entecavir treatment in children and adolescents with chronic hepatitis B virus infection. Chang KC, Wu JF, Hsu HY et al. Pediatr Neonatol. 2015 Dec 23 [Epub ahead of print]

 

08/02/16 Tacrolimus plus entecavir improves remission of HBV-associated glomerulonephritis
News Type: Clinical News

Tacrolimus with entecavir was fast and effective at inducing remission of HBV-associated glomerulonephritis in adults, a Chinese study reported.

The study authors have suggested the two may have a synergistic antiviral effect used together.

In the study, at Guangdong General Hospital, 23 HBV patients with biopsy-proven membranous nephropathy received tacrolimus (0.05mg/kg/day) in combination with entecavir over 24 weeks, whereas 19 received entecavir monotherapy.

The probability of proteinuria remission in the combination group was 69% after 12 weeks and 87% after 24, while in the monotherapy group it was 26% and 42%, respectively.

The mean time to partial or complete remission was 18.6 weeks in the combination patients and 34.3 weeks in the monotherapy group. There was a decrease in the HBV DNA titre in all patients with active HBV replication. None of the HBV carriers in the combination group showed evidence of HBV reactivation. The serum creatinine and alanine aminotransferase levels remained stable in both groups. The tacrolimus target trough concentration was 5-10ng/ml.

Reference

The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication. Wang L, Ye Z, Liang H et al. Clin Chim Acta. 2016 Jan 22 [Epub ahead of print]

08/02/16 Increasing prevalence of cirrhosis among US adults with HCV
News Type: Clinical News

The proportion of HCV-infected Americans with cirrhosis increased from 6.6% to 17.0% over the past two decades.

A new study found the prevalence of cirrhosis was highest among individuals who were unaware of their HCV infection.

Researchers at Stanford University School of Medicine used National Health and Nutrition Examination Survey (NHANES) data to identify adults with detectable serum HCV RNA. The prevalence of advanced fibrosis and cirrhosis was determined for Eras 1 (1988-94), 2 (1999-2006) and 3 (2007-12) by using FIB-4 > 3.25 and APRI > 2.0, respectively.

Out of 52,644 NHANES examinees, 49,429 were tested for HCV, of whom 725 met the inclusion criteria (positive HCV RNA with available data for FIB-4 and APRI). Based on APRI, 6.6% of HCV-infected adults in Era One, 7.6% in Era Two and 17.0% in Era Three had cirrhosis.

In the multivariable regression analysis, this era effect was attributable to increasing age (odds ratio 1.04), diabetes (odds ratio 2.33) and obesity (odds ratio 2.96). Cirrhosis was as common among respondents who were unaware of their infection as those who were aware (both 11%). Results were identical when FIB-4 was used.

The researchers say these data highlight the urgency for HCV screening regardless of symptoms, systematic assessment for liver fibrosis in those with HCV infection and institution of antivirals to prevent advanced liver disease.

Reference

Increasing prevalence of cirrhosis among US adults aware or unaware of their chronic hepatitis C virus infection. Udompap P, Mannalithara A, Heo N et al. J Hepatol. 2016 Jan 22 [Epub ahead of print]

03/02/16 Treatment Recommendations for the management of patients with Chronic HCV Infection – for consultation
News Type: BASL News

Recommendations were developed at a consensus meeting of clinicians and interested parties on 5 January 2016.

To view the recommendations please click here -   Download Treatment Recommendations for the management of patients with Chronic HCV Infection - for consultation.pdf

Therapies that are NICE approved are presented in bold and those that are NICE unapproved are italicised. The prices of the different regimens vary considerably. Clinicians should use the most cost effective treatment option taking account of the individual patient’s requirements.

The anticipation is that NHSE will adopt these recommendations for the networks and commission in line with our recommendations.

If you are interested in commenting please send your comments directly to Professor Graham Foster at g.r.foster@qmul.ac.uk before midday on 10th February 2016.

01/02/16 Entecavir can be genotoxic
News Type: Clinical News

New genetic studies show that the anti-HBV nucleotide analogue, entecavir, has a genotoxic effect. 

To evaluate its genotoxic mechanisms, researchers at Sichuan University, China, analysed the effect of entecavir on a panel of chicken DT40 B-lymphocyte isogenic mutant cell line deficient in DNA repair and damage tolerance pathways.

The results showed that Parp1-/- mutant cells defective in single-strand break (SSB) repair were the most sensitive to entecavir. Brca1-/-, Ubc13-/- and translesion-DNA-synthesis deficient cells including Rad18-/- and Rev3-/- were hypersensitive to entecavir.

XPA-/- mutant deficient in nucleotide excision repair was also slightly sensitive to entecavir. γ-H2AX foci forming assay confirmed the existence of DNA damage by  entecavir in Parp1-/-, Rad18-/- and Brca1-/- mutants. Karyotype assay further showed entecavir-induced chromosomal aberrations, especially the chromosome gaps in Parp1-/-, Brca1-/-, Rad18-/- and Rev3-/- cells when compared with wild-type cells.

The researchers concluded these genetic comprehensive studies clearly identified the genotoxic potentials of entecavir and suggested that SSB and postreplication repair pathways may suppress entecavir-induced genotoxicity.

Reference

Genetic evidence for genotoxic effect of entecavir, an anti-hepatitis B virus nucleotide analogue. Jiang L, Wu X, He F et al. PLoS One. 2016 Jan 22;11(1):e0147440

 

01/02/16 Impaired glucose metabolism increases death risk in HCV patients with cirrhosis
News Type: Clinical News

In compensated HCV-related cirrhotic patients, diabetes and marked insulin resistance are independently associated with poorer overall survival.

A new multicentre study also found an increased risk of hepatic decompensation in these patients.

A total of 250 subjects in Australia, Cuba and Spain, with compensated HCV-related cirrhosis and without known diabetes, underwent an oral glucose tolerance test and were subsequently followed for a median 201 weeks.

At baseline, 67 had Type 2 diabetes. During follow-up, 28 deaths and 55 first events of decompensation occurred. After adjustment for potential confounding covariates, overall mortality/liver transplant (hazard ratio 2.2) and hepatic decompensation events (hazard ratio 1.9) were significantly higher in those with diabetes.

Patients with a HOMA-IR >5 showed higher rates of mortality (hazard ratio 2.2). The rates of hepatic decompensation were higher in patients with HOMA-IR >3 (hazard ratio 1.7).

Overall, two-hour plasma glucose was the most robust predictor of overall mortality (hazard ratio 2.5) and decompensation (hazard ratio 2.7).

Reference

Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. Calzadilla-Bertot L, Vilar-Gomez E, Torres-Gonzalez A et al. Dig Liver Dis. 2015 Dec 25 [Epub ahead of print]

01/02/16 Alpha-fetoprotein as a biomarker for HCC in hepatitis patients
News Type: Clinical News

Two new studies demonstrate how alpha-fetoprotein (AFP) remains a valuable biomarker for predicting hepatocellular carcinoma (HCC) in hepatitis patients.

A Chinese study concluded that serum AFP was of diagnosis and prognostic predicting value for HCC with chronic HBV infection, and suggests its use as a biomarker in HBV endemic area like south east Asia (1).

Researchers from Peking University Health Science Centre studied 318 HBV patients, 731 cirrhosis patients and 796 HCC patients. Using 11.62ng/mL as a cut-off value, the positive rate of AFP test among serum HBsAg positive HCC patients was significantly higher than that in HBsAg negative HCC patients (79.55% versus 56.49%). Similarly, the median serum AFP level in HCC patients with serum HBsAg positive was significantly higher than that in those HBsAg negative HCC patients (423.89ng/ml versus 40.82ng/ml).

In addition, Kaplan-Meier curve analysis revealed that lower pre-operative AFP level implicated a much higher overall survival rate. Of note, such prognosis predicting value was only seen in those chronic HBV infection-related HCC patients, but not among the HCC patients aetiologically irrelevant to HBV infection.

A Brazilian study has suggested AFP could be used to distinguish between patients with HCC and cirrhosis or HCV, and that vascular endothelial growth factor (VEGF) could be a potential biomarker for HCC (2).

Researchers at Faculdade de Medicina de São José do Rio Preto evaluated the influence of the VEGF-C936T polymorphism on the prognosis of HCC, cirrhosis and HCV infection. A total of 285 subjects were studied: 68 HCC, 118 cirrhosis, 43 HCV, and 56 healthy controls.

The genotype CC (frequencies between 63.24% and 76.79%) and the C allele (absolute frequencies from 0.816 to 0.884) were prevalent in all groups. Higher VEGF levels in HCC patients (588.0 pg/mL) were observed, particularly in patients with the T allele in VEGF -C936T (764.4 pg/mL) compared to those in the other groups.

The same trend occurred with AFP levels (HCC 8.522; cirrhosis 12.7; HCV 4.6; control 2.7 ng/mL). Levels of VEGF and AFP showed sensitivity of 65% and 28% and specificity of 85 and 99%, respectively, for HCC patients.

References

1.          Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma. Yao M, Zhao J, Lu F. Oncotarget. 2016 Jan 13.[Epub ahead of print]

2.          Influence of vascular endothelial growth factor and alpha-fetoprotein on hepatocellular carcinoma. Yvamoto EY, Ferreira RF, Nogueira V et al. Genet Mol Res. 2015 Dec 21;14(4):17453-62 

01/02/16 New Recommended drinking guidelines welcomed by NICE
News Type: BASL News

NICE has welcomed proposed new guidelines on alcohol which aim to limit the health risks that result from drinking. The proposed guidelines, published by the Department of Health and out for consultation, make 3 main recommendations on safe levels of alcohol consumption".

Click here to read the article. 
 

Events

12/02/16 - 14/02/16 PGHTNCON 2016 - Jaipur India
News Type: Other Events

PGHTNCON 2016 - International Conference on Paediatric Gastroenterology Hepatobiliary, Transplant and Nutrition: Controversies and Consensus - New Dimensions to Explore.

Venue: Nims University Jaipur India.

The purpose of this meeting is to share knowledge of evidence-based practice in paediatric gastroenterology, hepatology, transplant and Nutrition with a view to improving paediatric patient care in view of paediatric gastroenterology, hepatology, transplant and Nutrition vis-a-vis all related fields.

Participants will have the opportunity to share their expertise in clinical practice and their knowledge with others to generate new perspectives and explore the new dimension of research.

To find out further information please click here.

20/02/16 - 24/02/16 25th Conference of the Asian Pacific Association for the Study of the Liver Tokyo, Japan
News Type: Other Events

APASL is one of the world’s three great liver societies along with AASLD and EASL. As the majority of global patients with liver disease are inhabitants of the region we represent, the Asia Pacific area, our role is to enhance the health of patients with liver disease by improving clinical practice through education and research. 

APASL has a particular role to play in advocacy, such as to engage governments, international societies and other related associations to establish mutual programs that will reduce the diffusion of hepatitis viruses, properly diagnosis patients and increase the availability of therapies to treat liver diseases. On behalf of the APASL Steering Committee and Executive Council, I would like to ask all members to give their ideas and suggestions so that our advocacy will be achieved.

The quality of research into liver disease accomplished by members of APASL has soared rapidly in recent years. The Tokyo conference will capture this growth and will allow researchers to enhance their research productivity. As more than 4,000 delegates of experts from all over the world are expected to attend this largest Asian Pacific liver conference, this will be the perfect opportunity for those of us in the Asian Pacific region to share state-of-the-art views, values, experiences and practices regarding liver diseases, such as Viral Hepatitis (A, B, C, and E), Liver Cancer, NASH, Liver Failure and other topics.

We are delighted to welcome you to the cultural, historical and scenic metropolis of Tokyo.

With warmest regards,

 

Osamu Yokosuka, MD., PhD.

President, The 25th Conference of the

Asian Pacific Association for the Study of the Liver

Professor of Gastroenterology and Nephrology, Chiba University Graduate School of Medicine

23/02/16 End of Life Care: Collaboration, Compassion, Choice
News Type: Other Events

Manchester Conference Centre

The End of Life Care: Collaboration, Compassion, Choice conference will help you to develop a greater understanding of how end of life care is going to be delivered in England over the next five years.

The programme will feature an overview of the latest policy and guidance from organisations such as NHS England and NICE, as well as further discussion around implementation and plans for the future. This will be supplemented by practical sessions which are designed to be transferable, encouraging adoption across different teams and organisations.


Further Informaiton Click HERE

25/02/16 - 26/02/16 Nottingham Postgraduate Course for the Gastro SCE (2016)
News Type: BASL Endorsed Events

The second Nottingham Postgraduate Course for the Gastroenterology Specialty Certificate Examination is being held at the Post Graduate Education Centre - Queen's Medical Centre, Nottingham NG7 2UH  

This 2 day BSG & BASL endorsed course is taking place on Thursday 25th to Friday 26th February. It is an event for Gastroenterology trainees of all grades, covering the breadth of the 2010 JRCPTB Gastroenterology curriculum. The course is tailored to help trainees prepare for the gastroenterology specialty certificate examination. This interactive course covers all the core topics including GI radiology, histopathology and endoscopy images reflective of the content of the examination. In addition sessions are included on examination technique with the opportunity for real-time mock examinations and quizzes for discussion.

To find out more and to book a place please click here

If you have any questions please contact the organiser by emailing gastroscecoursenottingham@gmail.com .

26/02/16 UKCPA Gastroenterology/Hepatology Group Masterclass - Caring for patients with Hepatitis C
News Type: BASL Endorsed Events

The UK Clinical Pharmacy Association Gastroenterology/Hepatology Group Masterclass - Caring for patients with Hepatitis C study day is being held at the Royal Pharmaceutical Society, 66—68 East Smithfield, London.

The aim of the day is to provide an introduction to Hepatitis C for pharmacists starting out in Hepatitis C and to update those with more experience. The day will also cover commissioning in light of the new NICE guidance.

Registration Fees:

BASL BVHG Members - £35.00
Non-Members - £135.00

The Fee includes a buffet lunch and refreshments.

To view the information flyer, please click here

For the Hepatitis C Masterclass Programme click here

Speakers include: 

Dr John McLauchlan, Associate Director, MRC-University of Glasgow Centre for Virus Research on Resistance and re-treatment

Malcolm Qualie, Pharmacy Lead, Specialised Services, NHS England on Commissioning and NICE TAs

Fiona Marra, Senior Pharmacist for HCV/HIV at Gartnavel hospital, Glasgow & Editorial board member Liverpool interactions website on Treatment of HCV

To register on line please click here.

07/03/16 - 08/03/16 St Mark Hospital's GastroSCE Course 2015
News Type: Other Events

The St Mark's Hospital (London) course is designed for registrars who are sitting their Gastroenterology Speciality Certificate Examination (SCE), and summarises the entire Gastroenterology course within 2 days, of which 1 day is specifically dedicated to all aspects of Hepatology.

The course has been running for the last two years, and is very popular. The course has been endorsed by BASL and by the British Society of Gastroenterology.

Please see last years programe below, the 2016 will offer similar content. Please note exact dates are to be confirmed.

Day 1 - Hepatobiliary 

08:30–09:00 Registration

09:00–10:00 Viral Hepatitis 

10:00–11:15 Break

11:15–11:45 ALD, NASH 

11:45–12:00 Break

12:00–13:00 Metabolic Liver Diseases, Liver Lesions 

13:00–13:30 Lunch

13:30–15:00 Autoimmune and Cholestatic Liver Diseases Pregnancy 

15:00–15:15 Break

15:15–16:15 Acute and Chronic Pancreatitis 

16:15–16:30 Break

16:30–17:00 ERCP images 

 

Day 2 - Luminal 

08:30–09:00 Registration

09:00–10:30 Upper GI (Physiology and Motility, GORD, Barrett’s, Oesophageal and Gastric Cancer, Peptic Ulcer disease)

10:30–10:45 Break

10:45–12:00 GI Bleed, Coeliac Disease, Small Bowel Baterial Overgrowth, Diarrhoea

12:00–12:15 Break

12:15–13:00 Vitamin (bsorption and deficiencies, small bowel resection and malabsorption, feeding 

13:00–13:30 Lunch

13:30–15:00 IBD (Epidemiology, Classification, Diagnosis, Management) 

15:00–15:15 Break

15:15–16:00 Radiology images 

16:00–16:15 Break

16:15–17:00 Endosocpy images 

For further details please click here or contact bahman.shokouhi@nhs.net 

11/03/16 BVHG Meeting - VIRAL HEPATITIS: Delivering HCV Treatment - London - Booking Now Open
News Type: BASL Events

Venue: The Royal College of Physicians, 1 St Andrews Place, Regents Park, London NW1 4LE

Topic: VIRAL HEPATITIS: Delivering HCV Treatment - what we are doing and where we should be going.

The BVHG meetings have been very successful, looking at a range of issues in viral hepatitis care, research, therapy and immunosuppression. We are continuing our themes by having this meeting examining how we deliver HCV treatments. Clinicians with significant experience in these fields will update us on present knowledge and practice and we hope that you can join us.

10.00 - 11.00  The Present – England - ODN and commissioning structure & plans - Claire Foreman

                        Examples of ODN working and best practice 
                        Greater Manchester Dr. Andrew Ustianowski
                        West Midlands Dr. Ahmed Elsharkawy
                        West London Prof Will Rosenberg
                        Wessex Dr Richard Aspenall

11.00 - 11.20  Coffee Break

11.20-11.40    Scotland: strategy and delivery Dr. Stephen Barclay TBC

11.40-11.55    Wales (& NI): strategy and delivery – Dr. Brendan Healy Public Health Wales

11.55-12.15    Panel discussion
12.15-13.00    Keynote Speaker –Reaching the unreachable - Prof. John Dillon NHS Tayside
13.00-13.40    Lunch
13.40-14.20    Symposium - by Bristol-Myers Squibb - Reality Check: The Real World HCV Experience
14.20-14.50    Debate: Speed up! Antivirals for the epidemic Dr Andy Ustianowski
                         Debate: Slow down! Antivirals for the liver disease Dr Will Gelson

14.50-15.15    Potential models for delivering care in the community – TBC
15.15-15.30    Coffee Break
                         Providing HCV care in offender health settings
15.30-15.50    Hep C Trust - Soon to be published Offender Health Report –Jane Cox
15.50-16.05    Panel discussion
16.05-16.20    Summary & close Dr. Ahmed Elsharkawy

Sponsors

Premier sponsors - Abbvie, Gilead Sciences, Bristol-Myers Squibb
Key sponsors - Merck Sharp & Dohme Ltd

Other parallel events:
Also on this day at the same venue the BVHG will be hosting the BVHG Maternal and Paediatric Sub-group meeting.

Contact
For any enquiries please contact the Secretariat on kim@basl.org.uk or admin@basl.org.uk +44 (0)1543 442154.

BOOKING
IMPORTANT *When completing the booking via the link below, please indicate meeting(s) you are attending in the Event Options section, so that we can we cater accordingly*
Registration Course cost:
Members of BASL/BVHG/BASLNF/BLTG - Free (*a £40 refundable deposit will be taken on booking*)
Non-members £45.00

*Members Refundable Deposit
For members, on completion of the booking form, a refundable deposit of £40 will be taken and will be returned to you after you have attended the event. If you do not attend the meeting and do not cancel your place within 2 weeks of the meeting, you may forfeit your deposit. Please see the cancellation policy below.
If you have any queries, please contact the Secretariat on kim@basl.org.uk or +44 (0)1543 442154.

Cancellation Policy
If you wish to cancel your attendance at this event, please contact the Secretariat no later than 14 days prior to the event. Bookings made within 14 days of the event cannot be refunded. Cancellations made outside of this time will be made at the sole discretion of BASL. If the event is free of charge to attend, cancellation as stated here may incur charges. By clicking confirm you accept these terms.

11/03/16 BVHG Maternal & Paediatric Sub Group Meeting - London - Booking Now Open
News Type: BASL Events

Venue: The Royal College of Physicians, 1 St Andrews Place, Regents Park, London NW1 4LE

Date: Friday 11th March 2016; 10:00 - 16:15

11th March 2016

________________________________________

Book via the Book Now link below


DRAFT Programme

Maternal and Paediatric Sub Group Meeting

10.00 - 11.00    Business meeting (for committee members)

11.00 - 11.20    Registration and Coffee

11.25 - 11.30    Welcome and introduction
11.30 - 13.00    Title of session
11.30 - 12.15    Causes of acute infective hepatitis in hospitalised children in the UK/Ireland - Dr Shamez Ladhani, Public Health England.

12.15 - 13.00    Advances in HBV Immunology - Dr Upkar Gill, Queen Mary University

13.00 - 13.40    Lunch

13.40 - 14.20    Symposium - by Bristol-Myers Squibb - Reality Check: The Real World HCV Experience

14.25 - 16.00    Title of session to be confirmed
14.25 - 15.10    Session Three - to be confirmed

15.10 - 16.00    Session Four - to be confirmed
16.00 - 16.15    Summary & close

Sponsors
Premier sponsors - Abbvie. Briston-Myers Squibb, Gilead.
Key sponsors - MSD

________________________________________
For queries, please contact admin@basl.org.uk Tel. 0845 521 0272 / 01543 442154

The last meeting in October 2015 was very successful, with excellent feedback received from delegates. This meeting will look at various issues within the maternal and paediatric field, including causes of acute infective hepatitis in hospitalised children. Clinicians with significant experience in the maternal and paediatric fields will update us on present knowledge and practice, and we hope you can join us.

Sponsors
Premier sponsors - AbbVie, Gilead Sciences, Bristol-Myers Squibb
Key sponsors - Merck Sharp & Dohme Ltd

Other parallel events
Also on this day at the same venue the BVHG will be hosting the BVHG meeting on Delivering HCV Treatments.

Contact
For any enquiries please contact the Secretariat on kim@basl.org.uk or admin@basl.org.uk  or by telephone on +44 (0)1543 442154.

BOOKING
IMPORTANT *When completing the booking via the link below, please indicate meeting(s) you are attending in the Event Options section, so that we can we cater accordingly*
Registration Course cost:
Members of BASL/BVHG/BASLNF/BLTG - Free (*a £40 refundable deposit will be taken on booking*)
Non-members £45.00

*Members Refundable Deposit
For members, on completion of the booking form, a refundable deposit of £40 will be taken and will be returned to you after you have attended the event. If you do not attend the meeting and do not cancel your place within 2 weeks of the meeting, you may forfeit your deposit. Please see the cancellation policy below.
If you have any queries, please contact the Secretariat on kim@basl.org.uk or +44 (0)1543 442154.

Cancellation Policy
If you wish to cancel your attendance at this event, please contact the Secretariat no later than 14 days prior to the event. Bookings made within 14 days of the event cannot be refunded. Cancellations made outside of this time will be made at the sole discretion of BASL. If the event is free of charge to attend, cancellation as stated here may incur charges. By clicking confirm you accept these terms.

Announcements

BASL Treasurer Post - nominations by Monday 8th February, 17:00

Please click here for more information.

December Newsletter available >here

January Events Update available >here

Learning Toolkits

The BASL Nurse Toolkits were developed following conversations with nurse specialists. These and a later email survey identified training needs to help nurses meet the liver nurse competencies. To access the Learning Toolkits sign in as a BASL Member and click on Manage Account

Quick Links

BASL is connected to a number of national initiaives that you might be interested in.